Biotech Startups

Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology. Its first approved product treats acute migraine in adults, and the company pursues partnerships and licensing for small and large molecules.

1 investor

Impli develops implantable biotech devices that enable continuous monitoring of biological data, starting with hormone monitoring applications. The platform is designed to support personalized, preventive healthcare by tracking real-time shifts in stress, fertility, metabolism, and aging.

1 investor

Implicit BioScience develops therapeutic approaches targeting cardioimmunology, specifically using CD14 blockade to modulate immune responses in acute heart attack (STEMI) treatment. The company's work is validated through peer-reviewed research in leading cardiology journals.

1 investor

Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers. The company's AMT-002 candidate is designed to selectively block autoantigens that trigger autoimmunity in patients with the HLA-DQ8 genetic allele.

1 investor

Immunic is a clinical-stage biopharmaceutical company developing oral small molecule treatments for neurologic and autoimmune diseases with unmet medical needs.

1 investor

IMV Technologies develops artificial insemination and reproductive biotechnology products for animal reproduction and veterinary imaging, including semen collection and storage, wireless ultrasound, pregnancy confirmation, and reproduction data management. It serves farmers, veterinarians, and livestock producers, with a focus on sustainable farming and animal health.

1 investor

A clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases, targeting off-the-shelf and scalable treatments to improve patient access.

1 investor

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological tumors using its DeltEx platform (allogeneic, autologous, iPSC, and genetically modified approaches). Its lead candidates include INB-400 and INB-200 for glioblastoma and INB-100 for leukemia patients undergoing bone marrow transplantation.

1 investor

Incanthera develops and commercializes therapeutics derived from the Institute of Cancer Therapeutics in Bradford. The company operates a direct-to-consumer model with a global network of influencers and ambassadors, targeting multi-billion dollar markets outside the US.

1 investor

InCephalo develops compartment-locked cytokine therapeutics that deliver localized immune activation to brain tumors while avoiding systemic exposure, with a lead asset targeting glioblastoma and other CNS diseases. The company is advancing a preclinical-to-clinical biotech program toward first-in-human trials.

1 investor

Incérès develops natural biocontrol substances, including an insecticide that has received a derogatory marketing authorization, as alternatives to pesticides for protecting crops. It targets agricultural sectors in France, addressing pests such as the Asian fruit fly (Drosophila suzukii) and aphids.

1 investor

Incisive Genetics develops non-viral gene editing therapeutics using proprietary lipid nanoparticle delivery technology to treat genetic diseases by editing genes directly in target tissues. The company focuses initially on Huntington's disease and is advancing toward human clinical trials.

1 investor

Ínclita Seaweed Solutions develops seaweed-based active ingredients as sustainable alternatives to synthetic and land-based actives, using green extraction and biorefinery methods. It offers a proprietary portfolio of ready-to-use ingredients and co-develops tailor-made ingredients with brands' R&D teams in the marine biotechnology field.

1 investor

Incredible produces a low-sugar fruit juice marketed as containing 70% less sugar than regular juice, around 30 calories, and 5g of fiber while being 100% juice. The company sells the beverage to retail stores.

1 investor

Indegene provides technology-enabled commercial solutions and consulting services for life sciences and healthcare enterprises, helping them optimize customer experiences, content management, and data-driven decision-making across their commercial operations.

1 investor

InDevR develops off-the-shelf and custom analytical testing solutions, including its VaxArray microarray platform and multiplex immunoassays, for the development, optimization, and manufacturing of mRNA-, protein-, polysaccharide, conjugate, and viral vector-based vaccines. It serves vaccine developers and manufacturers with GMP- and 21 CFR Part 11-compliant assays used across R&D, clinical trials, and release testing.

1 investor

IndieBio was a startup accelerator and pre-seed investment program launched by SOSV in San Francisco in 2015, providing on-site bio-labs and funding to science founders across biotech, food, agriculture, industrial decarbonization, AI, therapeutics, and diagnostics. As of 2026 the program was rebranded to SOSV NY and SOSV SF, expanding its focus from bio to broader deep tech.

1 investor

Indigo BioAutomation provides software tools that use machine learning and artificial intelligence to improve laboratory operations and data analysis across multiple industries. The platform helps scientists accelerate their research work and decision-making through collaborative tools and data-driven insights.

1 investor

IndiTreat is a CE IVD-marked functional drug sensitivity test that uses patient-derived tumor organoids to guide personalized treatment decisions for metastatic colorectal cancer (mCRC) patients. It is aimed at healthcare professionals and oncologists as a complement to traditional biomarker testing.

1 investor

Biotechnology company developing a pharmacologic treatment for infantile jaundice.

1 investor

Infera converts natural language descriptions of lab experiments into executable protocols for laboratory instruments, managing protocol logic, vendor-specific configurations, data, and inventory across an integrated system.

1 investor

A consortium and organization working to accelerate the development of therapeutics, vaccines, and products to combat antimicrobial resistance (AMR) through multiple innovation platforms. The organization supports industry partners, particularly early-stage biotech startups, in advancing solutions to address this global health crisis.

1 investor

Infius Health manufactures in-vitro diagnostic kits that automate manual medical testing procedures. The company serves healthcare providers and laboratories requiring diagnostic solutions.

1 investor

Inflamalps is a biopharmaceutical company discovering anti-inflammatory and anti-microbial molecules, with its lead candidate INF101 targeting dry eye disease in ophthalmology. Since 2020 it has run a drug discovery program for novel anti-microbial molecules in partnership with academic and CRO partners across Europe and New Zealand.

1 investor